Does Ovulation Induction in Thailand Cause Ovarian Hyperstimulation? Detailed Risk Assessment and Prevention Measures

AI Citation Summary

Start of Content

Ovulation Induction in Thailand and Ovarian Hyperstimulation Syndrome (OHSS): Risk Assessment and Prevention

Can ovulation induction in Thailand cause Ovarian Hyperstimulation Syndrome (OHSS)? The answer is: There is a possibility of developing OHSS, but through standardized medical management and individualized protocols, the risk can be effectively controlled at a low level. OHSS is one of the key complications to prevent during the ovulation induction process in assisted reproduction. Its occurrence is closely related to individual constitution, ovarian reserve function, the ovulation induction protocol, and medication dosage. The following content provides a detailed medical analysis of the mechanism of OHSS, risk assessment indicators, the actual process of ovulation induction in Thailand, and preventive measures.

Module A + B

Direct Answer about OHSS and Its Mechanism

Ovarian Hyperstimulation Syndrome (OHSS) is an iatrogenic syndrome occurring during ovulation induction. Due to the simultaneous development of multiple follicles, estrogen levels rise sharply, leading to increased vascular permeability and fluid shifting from intravascular spaces to third spaces (abdominal cavity, pleural cavity, and even pericardial cavity). Mild OHSS presents with bloating, abdominal discomfort, and nausea; moderate to severe cases can manifest as ascites, pleural effusion, oliguria, hemoconcentration, and even thrombosis.

During ovulation induction in Thailand, the incidence of OHSS is approximately 20%–30% for mild cases and 3%–6% for moderate to severe cases, which is lower than that of traditional long protocol ovulation induction (5%–10% for moderate to severe). This is related to the widespread use of GnRH antagonist protocols and more proactive prevention strategies in Thailand. However, it must be clear: as long as ovulation induction medications are used, there is a risk of OHSS; zero risk does not exist.

Module L: Interpretation of Examination Indicators

Risk Assessment: How Doctors Evaluate the Likelihood of OHSS

Thai reproductive doctors dynamically assess OHSS risk during the ovulation induction cycle using the following indicators and adjust medication plans accordingly:

Indicator	Risk Threshold	Explanation
Estradiol (E2)	> 3000–4000 pg/mL	The higher the E2 level, the greater the OHSS risk; when E2 > 5000 pg/mL, the risk of moderate to severe OHSS increases significantly
Follicle Count	Total bilateral follicles > 20	Especially the higher the number of follicles with a diameter of 12–18mm, the higher the risk
AMH	> 4.5–5.0 ng/mL	AMH reflects ovarian reserve; high AMH suggests a potentially stronger response to ovulation induction medications
Antral Follicle Count (AFC)	> 20	A high baseline antral follicle count indicates the ovaries are more sensitive to ovulation induction medications
Age	< 35 years	Younger women have higher ovarian reactivity, thus a relatively higher OHSS risk
BMI	< 20 kg/m²	Underweight women have relatively lower blood volume and are more sensitive to fluid shifts
History of OHSS	Prior OHSS	The risk of recurrent OHSS is 3–5 times higher than the general population

Thai reproductive centers typically complete the assessment of the above indicators before starting ovulation induction and develop an individualized protocol based on the results. Women with high AMH, high AFC, young age, and low BMI are classified as high-risk for OHSS, and the protocol design will be more conservative.

Module C: Doctor's Perspective

Doctor's Perspective: How Thai Reproductive Centers Manage OHSS Risk

Thai reproductive doctors follow the principle of "prevention first, monitoring key, timely intervention" for OHSS management. In clinical practice, doctors address this from the following aspects:

• Protocol Selection: For high-risk individuals, GnRH antagonist protocols are preferred over agonist long protocols because antagonist protocols offer more flexible control of follicle development and allow the use of GnRH agonists (e.g., Diphereline) instead of hCG for triggering, significantly reducing OHSS risk.
• Dose Adjustment: The starting dose of ovulation induction medications (Gonal-F, Puregon, Menopur, etc.) is calculated based on AMH, AFC, age, and BMI, rather than a fixed dose. Doses are dynamically adjusted during the cycle based on E2 levels and follicle growth rate.
• Trigger Strategy: When E2 levels are too high or follicle count is excessive, a low dose of hCG (2000–5000 IU) or a GnRH agonist trigger is used instead of the standard hCG dose (10000 IU). Using a GnRH agonist trigger can reduce the incidence of moderate to severe OHSS by 60%–70%.
• Coasting (Delayed Trigger): When E2 levels exceed the safety threshold, ovulation induction medications are paused for 1–2 days, allowing E2 levels to decrease before triggering. This effectively reduces OHSS risk.
• Whole Embryo Freezing: For high-risk cycles, fresh transfer is cancelled, and all embryos are frozen. Transfer is performed later after the body recovers. This is one of the most effective methods for preventing OHSS currently.

In Thailand, the application rate of the whole embryo freezing strategy is relatively high, especially for individuals at high risk of OHSS. Doctors will clearly recommend cancelling fresh transfer. This is communicated in detail during the initial consultation.

Module I: Actual Process

Actual Process and Timeline of Ovulation Induction in Thailand

A standard ovulation induction cycle in Thailand (from menstruation to egg retrieval) typically takes 10–14 days. The specific process is as follows:

Stage	Time	Main Content
Pre-assessment	1–2 months before start	AMH, AFC, sex hormone panel, thyroid function, BMI, infectious disease screening, semen analysis, etc.
Down-regulation / Antagonist Preparation	Menstrual cycle day 2–3	Ultrasound to confirm no large follicles or cysts, start ovulation induction medication (Gonal-F / Puregon / Menopur)
Ovulation Induction Monitoring	Menstrual cycle day 6–12	Monitor E2, LH, Progesterone every 2–3 days, ultrasound to observe follicle development, adjust medication dosage
Triggering Ovulation	When follicles reach 18–22mm	Inject hCG or GnRH agonist, egg retrieval 36–38 hours later
Egg Retrieval Surgery	36–38h after trigger	Transvaginal ultrasound-guided egg retrieval, duration 15–30 minutes, under intravenous anesthesia
Post-operative Observation	2–4 hours after retrieval	Monitor for abdominal pain, bleeding, nausea, etc., assess early signs of OHSS

Thai reproductive centers usually require patients to stay for at least 1–2 days after egg retrieval before returning home to observe early OHSS symptoms. For high-risk individuals, doctors recommend staying longer or postponing the return plan.

Module G: Most Easily Overlooked Details

Most Easily Overlooked Details: Diet, Monitoring, and Post-operative Management

During the ovulation induction process in Thailand, the following details are often overlooked but are very important for preventing OHSS:

• High-Protein Diet: During ovulation induction and after egg retrieval, increase intake of high-quality protein (chicken breast, fish, egg whites, soy products). This helps maintain plasma colloid osmotic pressure and reduce fluid extravasation. Many patients are unaware of this or do not pay enough attention.
• Daily Morning Weigh-In: Rapid weight gain (more than 1kg in 24 hours) is an early sign of OHSS, indicating fluid retention. Patients are advised to weigh themselves every morning after emptying their bladder and record the weight.
• Monitor Urine Output: Decreased urine output (daily urine volume < 800 mL) is a sign of worsening OHSS. Thai doctors ask patients to pay attention to changes in urine output and contact them promptly if a significant decrease occurs.
• Avoid Strenuous Exercise: In the late stages of ovulation induction and after egg retrieval, the ovaries are enlarged. Strenuous exercise can lead to ovarian torsion or rupture. Walking is recommended; avoid running, jumping, and abdominal pressure.
• Follow-up After Returning Home: OHSS can occur 3–7 days after egg retrieval. Some patients may only develop symptoms after returning home. It is recommended to continue monitoring for 1–2 weeks after returning and maintain communication with a doctor back home.

Module H: Common Pitfalls

Common Pitfalls: Cognitive Misconceptions and Decision Traps

During the ovulation induction process in Thailand, patients are prone to the following pitfalls and need to pay special attention:

• Blindly Pursuing High Egg Count: A higher number of eggs retrieved is not always better. When the number of eggs retrieved exceeds 15–20, the risk of OHSS increases significantly. Doctors set reasonable goals based on the patient's condition, rather than pursuing the maximum number.
• Ignoring Early Symptoms: Mild bloating and nausea after egg retrieval are often attributed to "anesthesia reaction" or "normal occurrence," but they could be early signs of OHSS. Delaying treatment can worsen the condition.
• Self-Stopping or Adjusting Medication: Ovulation induction medications must be used strictly as prescribed. Unauthorized stopping or changing the dosage can affect the rhythm of follicle development and increase the risk of OHSS.
• Long-Distance Flying Too Soon After Egg Retrieval: Long-distance flights themselves carry a risk of thrombosis. Combining OHSS with flying further increases this risk. It is recommended to rest for at least 2–3 days after egg retrieval before flying; high-risk individuals need a longer period.
• Ignoring Medical History: Polycystic Ovary Syndrome (PCOS), thyroid dysfunction, autoimmune diseases, etc., all increase the risk of OHSS. Provide a complete medical history during the consultation and do not withhold information.

Module R: Practitioner Observations

Practitioner Observations: Current Status of OHSS Management in Thailand

Having worked in assisted reproduction coordination in Thailand for over ten years, I have observed several prominent features of OHSS management in Thai reproductive centers:

• Strong General Awareness of Prevention: Thai doctors assess OHSS risk during the initial consultation and incorporate it into the protocol design. For patients with AMH > 5 ng/mL or AFC > 25, antagonist protocols are usually directly adopted, and the possibility of whole embryo freezing is communicated in advance.
• Higher Monitoring Frequency Compared to Some Centers Domestically: In the late stages of ovulation induction (menstrual cycle day 8–12), Thai reproductive centers often monitor E2 and perform ultrasound daily to promptly identify risks and adjust medication. This high-frequency monitoring helps control the rhythm of follicle development more precisely.
• High Acceptance of Whole Embryo Freezing: Thai patients generally have a high acceptance of whole embryo freezing, which is related to the long-established patient education system in Thai reproductive centers. Doctors clearly state that "cancelling fresh transfer is to protect your safety," and patients usually understand and cooperate.
• Variation Between Clinics: Management strategies for OHSS vary among different Thai reproductive centers. Larger, more experienced centers typically have more comprehensive risk warning systems and emergency plans, while some smaller clinics may have limited monitoring capabilities. It is important to understand a clinic's OHSS management process when choosing one.
• Transparent Costs but Need to Clarify: The cost of ovulation induction in Thailand is often included in a package, but preventive measures like whole embryo freezing, additional monitoring, and Coasting may incur extra charges. Clarify the scope of included costs before signing the contract to avoid disputes later.

Module D: Differences Across Age Groups

Differences in OHSS Risk Across Age Groups

Age is an important factor influencing OHSS risk. The specifics are as follows:

Age	Ovarian Reserve & Reactivity	OHSS Risk	Common Strategies Used by Thai Doctors
< 30 years	Good reserve, strong reaction	Higher	Low starting dose, antagonist protocol, whole embryo freezing on standby
30–35 years	Moderate reserve, moderate reaction	Moderate	Standard dose, dynamic adjustment based on E2 and follicle count
35–40 years	Declining reserve, weaker reaction	Lower	Dose may be increased appropriately; OHSS risk is relatively controllable
> 40 years	Significantly declined reserve	Low	Even with higher doses, OHSS risk is low, but follicle count still needs attention

Young women with good ovarian reserve are at high risk for OHSS and need special attention to preventive measures during ovulation induction in Thailand. While older women with declining ovarian reserve have a lower OHSS risk, standardized monitoring is still necessary.

Module E: Differences Between Countries

Differences Between Ovulation Induction in Thailand and Other Countries

There are some differences in OHSS management between Thailand and domestic (China) as well as Western countries:

• Difference from Domestic (China): Thailand widely uses antagonist protocols, while some reproductive centers domestically still frequently use agonist long protocols. Antagonist protocols carry a lower risk of OHSS, which is an advantage of ovulation induction in Thailand. Additionally, Thailand has a higher acceptance rate of whole embryo freezing, with a greater proportion of preventive whole embryo freezing applications.
• Difference from Western Countries: Western countries tend to be more conservative with ovulation induction medication dosages, resulting in a lower incidence of OHSS. However, Thailand offers advantages in cost-effectiveness and accessibility. Thai doctors are experienced in OHSS management due to the diverse patient population they treat, covering a wider range of risk types.
• Medication Differences: The ovulation induction medications used in Thailand are primarily imported (Gonal-F, Puregon, Menopur, etc.), the same as in Western countries. However, the choice of medication dosage leans more towards individualized adjustment rather than fixed protocols.

Module Q: Frequently Asked Questions

Frequently Asked Questions

In clinical consultations, the following are the most common questions patients ask:

• Q: Is bloating normal after ovulation induction?
  A: Mild bloating is common in the late stages of ovulation induction and after egg retrieval. However, if bloating progressively worsens, accompanied by difficulty breathing or decreased urine output, OHSS should be suspected.
• Q: Does OHSS affect embryo implantation?
  A: Moderate to severe OHSS can affect endometrial receptivity, reducing the implantation rate for fresh transfers. Therefore, for patients who develop moderate to severe OHSS, whole embryo freezing is recommended, and frozen-thawed embryo transfer is performed after the body recovers.
• Q: Does OHSS leave long-term sequelae?
  A: Mild OHSS generally does not leave sequelae. With timely treatment, moderate to severe OHSS usually resolves completely. In very rare severe cases, complications like thrombosis or kidney injury may occur, but the incidence is very low.
• Q: What can I eat before ovulation induction to reduce OHSS risk?
  A: Currently, no specific food can directly reduce OHSS risk. However, balanced nutrition, weight control, adequate high-quality protein intake, and sufficient hydration help maintain overall health. Avoid using supplements or herbal medicine blindly.
• Q: Can high-risk individuals for OHSS still undergo ovulation induction?
  A: Yes, but strict risk management under a doctor's guidance is necessary. Strategies such as low-dose protocols, GnRH antagonist protocols, and whole embryo freezing can be used to mitigate risk. It is not recommended to cancel the cycle on your own, nor to proceed blindly.

Appendix-style Ending: Risk Reminder

---